Paris 12 Val de Marne University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01086735
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (4)

chlorhexidine (hibitane) (1 trial)

colistin (1 trial)

nystatin (mycostatin) (1 trial)

tobramycin (nebcin) (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic lymphocytes (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteremia (Phase 3)

Neoplasms (Phase 2)

Suicide (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5